Wellgistics Health Collaborates with TheracosBio for Expanded Diabetes Medication Access

Wellgistics Health, Inc. (NASDAQ:WGRX) has announced a strategic partnership with TheracosBio to broaden access to Brenzavvy®, an FDA-approved diabetes therapy. This collaboration aims to provide affordable and nationwide availability of the medication through 6,500+ pharmacies. The initiative leverages Wellgistics Health's direct distribution platform, bypassing costly intermediaries to reduce costs.

Brenzavvy®, a once-daily oral SGLT-2 inhibitor, aims to aid glycemic control in adults with type 2 diabetes when combined with diet and exercise. The partnership seeks to tackle the high cost burdens on patients, with an emphasis on pharmacist empowerment through patient counseling and care coordination.